Literature DB >> 15270595

Intranasal medications for the treatment of migraine and cluster headache.

Alan M Rapoport1, Marcelo E Bigal, Stewart J Tepper, Fred D Sheftell.   

Abstract

Intranasal medications for the treatment of headache have recently received increased attention. This paper reviews intranasal formulations of a variety of available medications (dihydroergotamine mesylate [dihydroergotamine mesilate], sumatriptan, zolmitriptan, butorphanol, capsaicin and lidocaine [lignocaine]) and one experimental medication (civamide, a cis-isomer of capsaicin) for the treatment of migraine and cluster headache. Although the efficacy of intranasal agents varies with the product used, intranasal delivery may be both convenient and more effective than other modes of drug delivery for a variety of reasons: (i) intranasal administration bypasses small bowel gastrointestinal tract absorption, which is often significantly delayed during the acute phase of a migraine attack; (ii) nauseated patients may prefer non-oral formulations as they decrease the chance of vomiting and are more rapidly effective; (iii) intranasal administration causes no pain or injection site reaction and is easier and more convenient to administer than injection or suppository and so may be used earlier in a migraine attack, resulting in better efficacy; (iv) intranasal medication produces the same number or fewer adverse events than injections; and (v) intranasal formulations offer a more rapid onset of action than oral medications, for some of the above reasons and, as such, may be more useful in patients with cluster headache, although this needs to be verified. However, it is important to emphasise that a preference study showed that most patients prefer oral tablets to an intranasal formulation. Also, some nasal preparations have significant adverse effects or are not well absorbed and therefore do not work consistently; others are more challenging to administer as a result of their delivery apparatus. Nevertheless, it is our opinion that nasal preparations increase therapeutic options and may result in faster response times and better efficacy than oral formulations and better patient satisfaction than injectable preparations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15270595     DOI: 10.2165/00023210-200418100-00004

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  52 in total

Review 1.  The clinical spectrum of migraine.

Authors:  H J Blumenthal; A M Rapoport
Journal:  Med Clin North Am       Date:  2001-07       Impact factor: 5.456

2.  Prevalence and incidence of cluster headache in the Republic of San Marino.

Authors:  C Tonon; S Guttmann; M Volpini; S Naccarato; P Cortelli; R D'Alessandro
Journal:  Neurology       Date:  2002-05-14       Impact factor: 9.910

3.  Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine.

Authors:  S Diamond; A Elkind; R T Jackson; R Ryan; S DeBussey; M Asgharnejad
Journal:  Arch Fam Med       Date:  1998 May-Jun

4.  Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies.

Authors:  R Ryan; A Elkind; C C Baker; W Mullican; S DeBussey; M Asgharnejad
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

5.  One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study.

Authors:  A D Rothner; P Winner; R Nett; M Asgharnejad; A Laurenza; R Austin; M Peykamian
Journal:  Clin Ther       Date:  2000-12       Impact factor: 3.393

Review 6.  Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors:  V L Perrin
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

7.  A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache.

Authors:  D R Marks; A Rapoport; D Padla; R Weeks; R Rosum; F Sheftell; F Arrowsmith
Journal:  Cephalalgia       Date:  1993-04       Impact factor: 6.292

8.  A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group.

Authors: 
Journal:  Eur Neurol       Date:  1991       Impact factor: 1.710

9.  Office-based treatment of acute migraine with dihydroergotamine mesylate.

Authors:  P Winner; D Dalessio; N Mathew; C Sadowsky; L J Turkewitz; F Sheftell; S D Silberstein; S Solomon
Journal:  Headache       Date:  1993-10       Impact factor: 5.887

10.  Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial.

Authors:  Andrew J Dowson; Bruce R Charlesworth; Allan Purdy; Werner J Becker; Steen Boes-Hansen; Markus Färkkilä
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more
  20 in total

1.  Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures.

Authors:  Neil J Johnson; Leah R Hanson; William H Frey
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

2.  Reactive intermediates produced from the metabolism of the vanilloid ring of capsaicinoids by p450 enzymes.

Authors:  Christopher A Reilly; Fred Henion; Tim S Bugni; Manivannan Ethirajan; Chris Stockmann; Kartick C Pramanik; Sanjay K Srivastava; Garold S Yost
Journal:  Chem Res Toxicol       Date:  2012-11-06       Impact factor: 3.739

3.  A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis.

Authors:  Jonathan A Bernstein; Benjamin P Davis; Jillian K Picard; Jennifer P Cooper; Shu Zheng; Linda S Levin
Journal:  Ann Allergy Asthma Immunol       Date:  2011-06-29       Impact factor: 6.347

Review 4.  Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine.

Authors:  Alan M Rapoport; Fred Freitag; Starr H Pearlman
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 5.  Sumatriptan. An updated review of its use in migraine.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

6.  Efficacy and safety of transnasal butorphanol for pain relief after anal surgery.

Authors:  Chen-Ming Mai; Liang-Tsai Wan; Yu-Ching Chou; Hsiang-Yu Yang; Chang-Chieh Wu; Shu-Wen Jao; Cheng-Wen Hsiao
Journal:  World J Gastroenterol       Date:  2009-10-14       Impact factor: 5.742

Review 7.  [Pathophysiology of migraine and clinical implications].

Authors:  M Schürks; H-C Diener
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

8.  Cluster headache treatment dilemmas: the experts respond.

Authors:  Elizabeth Loder; Paul Rizzoli; Brian McGeeney; Thomas Ward; Morris Levin; Robert E Shapiro; Stewart Tepper; Larry Newman; Fred Sheftell; Alan Rapoport; Herbert Markley
Journal:  Curr Pain Headache Rep       Date:  2007-04

9.  Relevance of absorption rate and lag time to the onset of action in migraine.

Authors:  Hugo J Maas; Marc A H Spruit; Meindert Danhof; Oscar E Della Pasqua
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 10.  Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch.

Authors:  P Anand; K Bley
Journal:  Br J Anaesth       Date:  2011-08-17       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.